COMPANY NEWS Our new Roseville office is a hit! Weve had rave reviews about our new office. Patients like the spacious environment, the product displays, are awaiting pictures to be hung on the walls, and wondering what will be showing on TV. We are working on this and will surprise you soon. We look forward to making the new Roseville office and our beautiful Sacramento location your place to become motivated and inspired to continue your journey in obtaining optimum health, weight and wellness. New address: 2510 Douglas Boulevard, Suite 200, Roseville. SPECIAL OF THE MONTH - Another New Product: Last month, we sampled a granola-style cereal called Berry Good Cereal which has NO grains and a great protein to carbohydrate ratio we approve. The cereal comes in a 1 pound bag; 16 servings per bag. We recommend a 1/4 cup serving, which provides 5.5 grams of protein, 4 net carbs, and 10 grams of fat. See below for recipe i

Read More →

Does phentermine induce or provoke relapse of substance abuse? Statement of the Issue: FDA drug labeling and the PDR state that phentermine is contraindicated in patients with a history of drug abuse. The FDAs hypothesis is that phentermine, a category IV controlled substance, prescribed for such patients can provoke relapse of drug abuse (first hypothesis). A corollary hypothesis, which must also be true for the first hypothesis and the FDAs contraindication to be valid, is that phentermine has significant human addiction potential (second hypothesis). Origin of the Issue & Historical perspective: Phentermine was approved for marketing by the FDA in 1959. At the time phentermine was approved, far less was understood of the nature of stimulant drug abuse than is the case today. At that time, the favored hypothesis was that stimulant abuse potential was directly correlated to stimulant potency. No suggestion of abuse or depe

Read More →

Does phentermine induce or provoke relapse of substance abuse? Statement of the Issue: FDA drug labeling and the PDR state that phentermine is contraindicated in patients with a history of drug abuse. The FDAs hypothesis is that phentermine, a category IV controlled substance, prescribed for such patients can provoke relapse of drug abuse (first hypothesis). A corollary hypothesis, which must also be true for the first hypothesis and the FDAs contraindication to be valid, is that phentermine has significant human addiction potential (second hypothesis). Origin of the Issue & Historical perspective: Phentermine was approved for marketing by the FDA in 1959. At the time phentermine was approved, far less was understood of the nature of stimulant drug abuse than is the case today. At that time, the favored hypothesis was that stimulant abuse potential was directly correlated to stimulant potency. No suggestion of abuse or depe

Read More →

Arena Pharmaceuticals announced today that the company has submitted their application to the US Food and Drug Administration (FDA) for marketing approval for Lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The press release indicated the submission is based on an extensive data package from lorcaserin's clinical development program that includes 18 clinical trials totaling 8,576 patients. Now the waiting begins to see if the FDA will approve this novel drug.

Read More →

Arena Pharmaceuticals announced today that the company has submitted their application to the US Food and Drug Administration (FDA) for marketing approval for Lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The press release indicated the submission is based on an extensive data package from lorcaserin's clinical development program that includes 18 clinical trials totaling 8,576 patients. Now the waiting begins to see if the FDA will approve this novel drug.

Read More →

History Human Chorionic Gonadotropin (HCG) is a hormone normally secreted by the trophoblastic cells of the placenta during pregnancy. It was first described as a treatment for obesity in conjunction with a very low calorie diet by Dr. A. Simeons in 1954 [1]. The Simeons method consisted of a rigid diet of about 500 calories per day combined with 125 units of HCG injected six days per week for 8 weeks. For each of the two meals permitted daily, patients were instructed to select one item from each of four food groups, protein, vegetable, bread, and fruit. For protein servings patients were told to select from the following list: 3.5 ounces of meat, 3.75 ounces of fish, 4 ounces of Hoop cheese, or 6 egg whites. The latter two choices were to be selected occasionally [2]. The protein intake on the Simeons diet therefore ranged from about 45 to 50 grams per day. The Simeons method was very popular in the 1970s and advocates claimed that the method had

Read More →

Arena Pharmaceuticals released today the first report of their initial 2-year phase 3 clinical trial for Lorcaserin. Although Wall Street analyists generally issued pessimistic opinions, careful analysis reveals that the newdrugmeets or exceedsFDA standardsfor approval.Furthermore the weight loss results are robust withnearly 50% of patients losing 5% of initial weight and nearly 25% losing 10%.Typically there is a marked genetic variation inpatient response to obesity treatment, something FDA trials tend to obscure. A high percentage of patients who lose more than 5 and 10% suggestsa very large population of obese patients will respond with impressive weight loss with Lorcaserin. The drug triggers specific brain serotonin receptors known to diminish carbohydrate cravings and diminish food intake. Patients receiving agents known to stimulate these receptors often comment onhow easy it is to diet and lose weight.This factor alone should make this drug a very popular one

Read More →

Arena Pharmaceuticals released today the first report of their initial 2-year phase 3 clinical trial for Lorcaserin. Although Wall Street analyists generally issued pessimistic opinions, careful analysis reveals that the newdrugmeets or exceedsFDA standardsfor approval.Furthermore the weight loss results are robust withnearly 50% of patients losing 5% of initial weight and nearly 25% losing 10%.Typically there is a marked genetic variation inpatient response to obesity treatment, something FDA trials tend to obscure. A high percentage of patients who lose more than 5 and 10% suggestsa very large population of obese patients will respond with impressive weight loss with Lorcaserin. The drug triggers specific brain serotonin receptors known to diminish carbohydrate cravings and diminish food intake. Patients receiving agents known to stimulate these receptors often comment onhow easy it is to diet and lose weight.This factor alone should make this drug a very popular one

Read More →